Business Context and Reporting Period
This Form 8-K is a current report filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on March 30, 2011. The filing addresses a corporate governance event: the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Dr. Curtis A. Lockshin to the Board of Directors on March 30, 2011, to fill a vacancy on the seven-member board. Dr. Lockshin was also appointed as a member of the Compensation Committee. He will participate under the same compensation structure as other non-employee board members.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the disclosure of the director appointment and Dr. Lockshin's professional background in the biotechnology and pharmaceutical sectors.
Investor Verification Checklist
- Verify the correct registrant name is ChromaDex Corporation, not Niagen Bioscience, Inc.
- Confirm Dr. Curtis A. Lockshin's appointment to the Board and Compensation Committee.
- Review Dr. Lockshin's prior board service (Sorrento Therapeutics, Winston Pharmaceuticals, Orthodontix) for potential conflicts of interest.
- Note that no financial data is included in this specific filing; refer to 10-K or 10-Q for financial metrics.